Clinical meaning
The prescribing logic framework for pregnancy safety integrates embryologic timing, pharmacologic mechanism, and evidence-based risk classification to guide medication decisions during the reproductive period. The former FDA pregnancy letter categories (A, B, C, D, X), which were in use from 1979 to 2015, were fundamentally flawed because they implied a linear hierarchy of risk that oversimplified complex data — category C included 60% of all medications and provided no clinically actionable information. The 2015 Pregnancy and Lactation Labeling Rule (PLLR) replaced letters with narrative subsections providing human data summaries, animal data, pharmacokinetic considerations, and clinical implications. Prescribing logic requires understanding why specific drugs cause harm through their mechanisms: ACE inhibitors (lisinopril, enalapril) and ARBs (losartan, valsartan) are fetotoxic in the second and third trimesters because the fetal renin-angiotensin system is essential for nephron development and maintenance of fetal renal perfusion — inhibition causes renal tubular dysplasia, oligohydramnios (from decreased fetal urine output), pulmonary hypoplasia (from oligohydramnios), limb contractures, and skull ossification defects. Statins are contraindicated because cholesterol is essential for fetal cell membrane synthesis, steroid hormone production, and Hedgehog signaling pathway function (critical for limb patterning, CNS development, and facial morphogenesis). Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, blocking purine and pyrimidine synthesis essential for rapidly dividing fetal cells — first-trimester exposure causes aminopterin syndrome (craniosynostosis, limb defects, neural tube defects). The risk-benefit analysis must also consider the danger of untreated maternal disease: uncontrolled epilepsy poses greater risk to the fetus (hypoxia from seizures, trauma) than most antiepileptic drugs; uncontrolled asthma causes fetal hypoxia more dangerous than inhaled corticosteroids (which are safe in pregnancy); and untreated HIV has 15-45% vertical transmission rate versus <1% with antiretroviral therapy. Pharmacokinetic changes in pregnancy alter drug levels: lamotrigine clearance doubles (requiring dose increases), lithium volume of distribution increases (requiring level monitoring every 2-4 weeks), and insulin requirements increase 2-3 fold by the third trimester due to hPL-induced insulin resistance.